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Abstract: Psoriasis is a chronic skin disease that results from the complex interaction between genetic and envi-
ronmental factors. Over the last few decades, scientific evidence has redirected the focus of therapeutic studies to
the immunologic pathways underlying its pathogenesis. This led to the biologic boom that we are currently expe-
riencing, with the development and approval of targeted progressively more selective biological therapies and
ongoing clinical trials of increasingly specific drugs, given their important implications for long-term efficacy and
safety. Nevertheless, the search for the optimal biologic is still ongoing, and the best target has yet to be found.
Keywords: Biological therapy; Cytokines; Psoriasis
Psoriasis is a chronic skin disease that results
from the complex interaction between genetic and
environmental factors.1 Over the last few decades, sci-
entific evidence has shown that the keratinocyte prolif-
eration that characterizes psoriasis is triggered by acti-
vated T-cells, thus redirecting the focus of therapeutic
studies to the immunologic pathways contributing to
its pathogenesis.2 This led to the biologic boom that we
are currently experiencing, with the development and
approval of progressively more selective targeted bio-
logical therapies and ongoing clinical trials of increas-
ingly specific drugs, given their important implica-
tions for long-term efficacy and safety.
The major pathogenic pathways involved in
psoriasis that scientific research has brought to light
so far comprise: the one involving interleukin (IL)-12,
composed of two subunits (p40 and p35), driving a T-
helper (Th)1 response; the IL-23/IL-17 axis, the former
composed by the p40 and p19 subunits and the later
with two isoforms, A and F, stimulating the expansion
of Th17 and Th22 cells and production of IL-17 and IL-
22 – now known to have key effects on the epidermis
and upregulating other proinflammatory cytokines
and growth factors, therefore creating a self-amplify-
ing inflammatory process; and tumor necrosis factor
(TNF)-α signaling, a pleiotropic cytokine pathway
that activates multiple immune cell types of both
innate and adaptive immunity (Figure 1).1,2
The first biologic therapies, namely alefacept
and efalizumab (withdrawn), acted by blocking T-
cells, suppressing overall cytokine production and
thus inhibiting the activation and proliferation of all
T-cell subtypes, with a broad effect on the immune
system and, consequently, wide-ranging potential
side effects.2-4 This prompted unceasing investigation
for more selective drugs.
TNF-α is a potent pro-inflammatory cytokine
with significant interactions with the other pathogen-
ic cytokines in psoriasis. Its blockade is thought to
improve psoriasis due to its impact in down-regulat-
ing IL-23, Th-17 cells, and, later, Th-1 related
genes.5 Etanercept, adalimumab, and infliximab are
approved for psoriasis, and new drugs are currently
undergoing clinical trials. As TNF-α plays also an
important role in innate immunity, resulting in broad
immunosuppression, the risk of infection and malig-
nancy with these therapies cannot be disregarded.5
Available anti-IL-12/IL-23 therapies, such as
ustekinumab, target the p40 subunits of the two
cytokines.6 Both the p19 and p40 subunits of IL-23 are
amplified in psoriasis, unlike IL-12p35, which is not
elevated; this suggests that IL-23 might have greater
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impact in psoriasis than IL-12.2 These drugs directly
inhibit T-cell activation, unlike anti-TNFα prepara-
tions, which act indirectly through the inhibition of
IL-23 by dendritic cells.2 Besides, the innate immunity
is not directly suppressed by inhibition of p40, with a
theoretically superior safety profile. Although more
selective, an additional refinement regarding this
inflammatory axis recently emerged, with an alternate
targeting of the p19 subunit of IL-23 alone, sparing the
p40 subunit and, consequently, not affecting the Th-1
driven response.2 This new approach and inhibition of
the IL-23 are currently being tested in phase II clinical
trials, in order to assess the potential benefits of
guselkumab and tildrakizumab.2
Regarding IL-17 inhibition, secukinumab is cur-
rently in phase III trials and ixekinumab in phase
II.7,8 Only the IL-17A isoform is targeted; according to
recent data, this approach has the advantage of main-
taining a high efficacy of blockade of this major
cytokine with a low risk of adverse events resulting
from immunosuppression, probably due to compen-
satory action by the other isoform, although the clini-
cal significance of these facts is not completely eluci-
dated.7,8 Nevertheless, acting selectively at the level of
a key effector cytokine might preserve the other cellu-
lar immune functions, so the spectrum of immuno-
suppression is undoubtedly narrower than with any
previous therapy, and the targeted molecules much
more specific to the pathogenesis of psoriasis, making
this a promising drug. IL-17 receptor blockers, such as
brodalumab, are also under phase II trials, with the
same potential benefits of the aforementioned agents,
but inhibiting multiple members of the IL-17 family
and so with a different side effect profile (which has
yet to be elucidated).9
Other possible pathways are under the scrutiny
of laboratory investigation, and IL-22 has appeared as
a promising target. It is strictly related to the critical
Th17/Th22 pathway, thus making it a smart option
for the therapy of psoriasis.10 Nevertheless, trials of
fezakinumab, an IL-22 antibody, were discontinued.10
In the era of biologics and with the advent of
genetic and molecular research, therapy targets are
becoming progressively more selective. The recogni-
tion of the major pathogenic pathways involved in
psoriasis and the knowledge of their clinical implica-
FIGURE 1: TNF-α inhibitors – act by blocking TNF-α, with impact on innate and adaptive immunity. IL-12/23 inhibitors – block the genera-
tion and maintenance of Th1 and Th17 cells. IL-23 inhibitor – acts selectively on the IL23/Th17pathway, preserving the IL-12/Th1 pathway.
IL-17A inhibitors – act selectively at the level of an effector cytokine, preserving other IL-17 producing cell functions. IL-17 receptor inhibi-
tors – act at the level of a shared IL-17 cytokine receptor, blocking multiple members of the IL-17 cytokine family (IL-17A/F/C/E).
Abbreviations: TNF, tumor necrosis factor; IL, interleukin; Th, T helper.
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tions prompted the emergence of numerous novel
therapies. The goal remains to achieve selective
immunosuppression with minimal side effects, as the
further downstream the target of blockade in the
inflammatory cascade, the lower the resultant
immunosuppression and the consequent risks of
infection and malignancy. Agents once considered
selective only some years ago will probably soon
be replaced by more recent and more focused ther-
apies. If we think we have come too far, much
remains to be done in the future, and further large,
controlled studies of recent drugs are needed to
clarify their role in the complex management of
psoriasis. q
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